$HRTX alerted yesterday, Heron Therapeutics, Inc. to Post

New Post Public Reply Private Reply Replies (0) Message Board
fitzkarz fitzkarz #15290
194
$HRTX alerted yesterday,
Heron Therapeutics, Inc. to Post FY2016 Earnings of ($4.35) Per Share, Leerink Swann Forecasts (HRTX)

Posted by Wayne Landers on Jan 10th, 2017 // No Comments

Heron Therapeutics logoHeron Therapeutics, Inc. (NASDAQ:HRTX) – Equities researchers at Leerink Swann issued their FY2016 earnings per share estimates for shares of Heron Therapeutics in a research note issued on Wednesday. Leerink Swann analyst J. Gerberry expects that the brokerage will earn ($4.35) per share for the year. Leerink Swann has a “Buy” rating and a $21.00 price objective on the stock. Leerink Swann also issued estimates for Heron Therapeutics’ Q4 2016 earnings at ($1.01) EPS, Q1 2017 earnings at ($0.86) EPS, Q2 2017 earnings at ($1.04) EPS, Q3 2017 earnings at ($0.80) EPS, Q4 2017 earnings at ($0.72) EPS, FY2017 earnings at ($3.38) EPS, FY2018 earnings at ($2.44) EPS, FY2019 earnings at ($0.75) EPS and FY2020 earnings at $1.26 EPS.

Other equities analysts have also recently issued reports about the company. Cowen and Company restated a “buy” rating and set a $40.00 target price on shares of Heron Therapeutics in a research report on Friday. Jefferies Group set a $29.00 target price on Heron Therapeutics and gave the stock a “buy” rating in a research report on Thursday, January 5th. Cantor Fitzgerald restated a “buy” rating and set a $34.00 target price on shares of Heron Therapeutics in a research report on Thursday, November 10th. JMP Securities restated a “buy” rating on shares of Heron Therapeutics in a research report on Wednesday, November 9th. Finally, Aegis started coverage on Heron Therapeutics in a research report on Wednesday, October 26th. They set a “buy” rating and a $41.00 target price for the company. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $37.75.

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ:HRTX) opened at 13.50 on Monday. Heron Therapeutics has a 52-week low of $12.30 and a 52-week high of $25.84. The firm has a 50-day moving average price of $14.54 and a 200 day moving average price of $17.06.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, November 8th. The biotechnology company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($1.17) by $0.07.

Large investors have recently added to or reduced their stakes in the stock. Franklin Resources Inc. raised its stake in Heron Therapeutics by 3.0% in the second quarter. Franklin Resources Inc. now owns 7,752,460 shares of the biotechnology company’s stock worth $139,937,000 after buying an additional 229,182 shares during the period. FMR LLC raised its stake in Heron Therapeutics by 1.2% in the second quarter. FMR LLC now owns 5,493,420 shares of the biotechnology company’s stock worth $99,156,000 after buying an additional 63,968 shares during the period. Janus Capital Management LLC raised its stake in Heron Therapeutics by 14.8% in the second quarter. Janus Capital Management LLC now owns 4,013,921 shares of the biotechnology company’s stock worth $72,450,000 after buying an additional 516,166 shares during the period. Baker BROS. Advisors LP bought a new stake in Heron Therapeutics during the third quarter worth $49,230,000. Finally, Vanguard Group Inc. raised its stake in Heron Therapeutics by 5.0% in the second quarter. Vanguard Group Inc. now owns 1,215,343 shares of the biotechnology company’s stock worth $21,937,000 after buying an additional 58,039 shares during the period.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mango Board Honors Retailers Boosting Mango Sales

Updated Category News Views 97

The Unsung Heroes of the Mango Aisle You ever look around a grocery store and wonder who's behind those flashy displays that make a mango seem like the most appealing fruit in the aisle? Well, this year, four retailers got their pat on the back from the National Mango Board for doing just that—H-E-B, Rouses, Nugget Market, and Superior Grocers. Let me tell you, these...

Continue Reading
ePlus Schedules Q2 2027 Earnings Call Amid Corrections

Updated Category News Views 119

Earnings Date: Mark Your Calendar Well, folks, the date is set. ePlus Inc. is gearing up to drop some numbers that could stir the markets a bit. Come November 5th, those eagle-eyed investors better be on their toes because that’s when we’re getting the scoop on ePlus' second-quarter results for the fiscal year 2027. The bell rings after the market closes, so pour...

Continue Reading
Democracy's Living History at Long Island University

Updated Category News Views 76

America’s democracy is getting its moment in the spotlight over at Long Island University, and it's more than just statues and old papers. This exhibition, "The Presidency & Promise of America: A More Perfect Union," unpacked on October 28, throws open a window into the U.S.'s democratic journey from its scrappy beginnings to today’s hot zones of political debate. And...

Continue Reading
FOX News Sweeps 2026 Midterms Coverage Ratings

Updated Category News Views 11

FOX News Outshines Rivals in Midterm Coverage Diving into the chaos of the 2026 midterm elections, it’s clear FOX News Media’s strategic playbook outmaneuvered its cable competitors, chalking up a dominant ratings victory. Nielsen's final count places FOX News Channel (FNC) in the spotlight, their primetime broadcast drawing nearly 4.7 million viewers. And while some...

Continue Reading
Planet Fitness Flexes Financial Muscle in Q3 2026

Updated Category News Views 228

Financial Performance and Strategic Shifts Amidst a flurry of strategic maneuvers, Planet Fitness (NYSE: PLNT) cranked out a mixed but promising set of financial results for the third quarter of 2026. Revenue jumped 9.0% from last year to hit $360 million, a solid figure even if it came with a slight decrease in net income. It's a dance between growth and caution, folks....

Continue Reading
Gundry MD Unleashes MyoPeptide: A Powerhouse Supplement

Updated Category News Views 52

Creatine Gets a Makeover with MyoPeptide Well, here we have it! Gundry MD just rolled out their newest concoction, MyoPeptide Complex, and she's not your run-of-the-mill creatine shake. Blending creatine monohydrate with PeptiStrong®, a fava bean peptide, plus a couple of vitamins, this new supplement claims to turbocharge strength, recovery, and even your cognitive...

Continue Reading
MDA Space Q3 2026: Growth, Cash Flow Surge

Updated Category News Views 68

Revving Up in the Space Game Alright, let's talk MDA Space (TSX:MDA). Their third-quarter numbers for 2026 are in, and boy, they're not just floating aimlessly in space—this company is rocketing upward. Revenue hit $498 million, a solid 22% jump from last year. The kind of boost you'd expect when you've got a $40 billion opportunity pipeline and some new shiny tech...

Continue Reading
Qfin Faces Stock Lawsuit: Know Your Investor Rights

Updated Category News Views 100

Qfin in the Legal Hot Seat When you hear about a company's legal wranglings, especially one like Qfin Holdings, Inc., you've got to sit up and take notice. We're not talking about a quick scuffle here; this is a full-blown class action lawsuit with its talons sunk deep into allegations of securities law violations. They're squared off against DJS Law Group, an outfit that...

Continue Reading
Co-Diagnostics Moves Up Q3 Earnings Release to Nov. 10

Updated Category News Views 17

Co-Diagnostics Shifts Its Calendar Well, well, well, Co-Diagnostics decided to shake up its calendar. What are they looking to spill before the weekend? They’ve bumped up their third quarter 2026 earnings release by two days—an eyebrow-raiser for folks watching NASDAQ:CODX. Now they'll lay it all out on November 10, after we wrap up the trading day. I don’t want to...

Continue Reading
International Book Launch Celebrates Chinese Garden Art

Updated Category News Views 126

Book Celebrates the Harmony of Nature and Culture The dusty pages of history crack open yet again, but this time with an aromatic whiff of oriental garden artistry. Some might say books and gardens don't share much beyond paper, mulch, and soil. But hold tight. This isn't just any old launch—it's the Harmony Between the Universe: International Perspectives on the Lion...

Continue Reading

Top 5 Most Recently Viewed Articles

Youth Seek Security in Civil Service Amid Economic Challenges

Updated Category News Views 246

Chinese Youth Turn to Civil Service for Stability The demand for civil service jobs among the youth in China has surged remarkably, with a staggering 3.4 million candidates registering for the civil service exam this year. This trend can be largely attributed to the allure of job security in the face of a struggling economy and rising youth unemployment rates. With...

Continue Reading
Crawler Dozers Market Growth Soars to USD 13.2 Billion

Updated Category News Views 202

Expanding Crawler Dozers Market and Its Drivers The crawler dozers market is experiencing dynamic growth, with estimates suggesting an increase from approximately USD 8.5 billion in a couple of years to a substantial USD 13.2 billion by 2034. This remarkable growth, attributed to a compound annual growth rate (CAGR) of 4.6%, reflects the increasing need for advanced...

Continue Reading
New Floating-Rate Bonds Initiative Enhancing Funding Solutions

Updated Category News Views 167

New Floating-Rate Bonds Initiative Enhancing Funding Solutions Realkredit Danmark is set to launch new mortgage covered bonds (SDRO) aimed at financing the RD Nibor3® and RD Stibor3® initiatives. This step marks a significant move in the company's efforts to enhance its funding solutions and refine existing financial structures. In an ever-evolving financial landscape,...

Continue Reading
Earnings Preview: What Investors Should Know About Coursera

Updated Category News Views 74

Understanding Coursera's Upcoming Earnings Report Coursera (NYSE: COUR) is set to release its quarterly earnings soon, and there is much anticipation surrounding this event. For investors looking to make informed decisions, understanding the key details and insights surrounding this announcement is crucial. Analysts are projecting an earnings per share (EPS) of $0.02, and...

Continue Reading
Quantum BioPharma Offers $7 Million Reward for Insider Tips

Updated Category News Views 189

Quantum BioPharma Announces Whistleblower Cash Reward Quantum BioPharma Ltd. (NASDAQ: QNTM) is making significant waves in the biopharmaceutical industry with its innovative strategy designed to combat stock manipulation. The company has launched a whistleblower policy that offers a remarkable cash reward of up to USD $7 million to those who provide concrete evidence...

Continue Reading